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Open access under CC BY-NC-ND license.SUMMARYLimited clinical benefits derived from anti-VEGF therapy have driven the identification of new targets involved
in tumor angiogenesis. Here, we report an integrative meta-analysis to define the transcriptional program
underlying angiogenesis in human cancer. This approach identified ELTD1, an orphan G-protein-coupled
receptor whose expression is induced by VEGF/bFGF and repressed by DLL4 signaling. Extensive analysis
of multiple cancer types demonstrates significant upregulation of ELTD1 in tumor-associated endothelial
cells, with a higher expression correlating with favorable prognosis. Importantly, ELTD1 silencing impairs
endothelial sprouting and vessel formation in vitro and in vivo, drastically reducing tumor growth and greatly
improving survival. Collectively, these results provide insight into the regulation of tumor angiogenesis and
highlight ELTD1 as key player in blood vessel formation.INTRODUCTION
Angiogenesis, defined as the formation of new blood vessels
from pre-existing ones, is a key process in normal developmentSignificance
Angiogenesis represents a rational therapeutic target critical f
common to different cancer types enabled us to characterize th
in response to antiangiogenic therapies. A relatively unstudied
angiogenic pathways and played an important role in blood
impaired tumor growth in vivo despite the association betw
and good prognosis in multiple cancer types. These data adv
ELTD1 as an important candidate for targeted therapies.and pathological conditions such as cancer. The proven role for
angiogenesis in providing oxygen and nutrients necessary for
tumor growth explains its clinical relevance and therapeutic
potential (Hanahan and Weinberg, 2011; Li and Harris, 2009).or solid tumor growth. Defining angiogenesis-related genes
e underlying core transcriptional programand itsmodulation
G-protein-coupled receptor, ELTD1, was regulated by key
vessel formation. Furthermore, ELTD1 silencing markedly
een high expression in tumor-associated endothelial cells
ance our knowledge of the angiogenic process and identify
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Figure 1. Derivation of Angiogenesis Meta-
signatures in Primary Human HNSCC, BC,
and CCRCC
Angiogenic profiles of 121 HNSCC (A), 959 BC (B),
and 170 CCRCC samples (C). The x axis repre-
sents seeds from highly overlapping clusters (see
Figure S1), and the y axis shows genes whose
expression clusters with the seeds; coloring
indicates strength of membership (see color
scale). Clustering on correlating expression
(membership; y axis) revealed the existence of
three distinct gene clusters associated with
different patient groups in HNSCC (A) and BC (B)
and two clusters with a more compact profile in
CCRCC (C). See also Table S1.
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ELTD1 and AngiogenesisDespite great promise in preclinical models, approved antian-
giogenic therapy has shown limited and transient efficacy due to
initial or acquired resistance (Carmeliet and Jain, 2011a). Thus,
the complex molecular programs regulating angiogenesis have
been extensively studied to discover both new targets and pre-
dictive markers.
Several approaches have been exploited (van Beijnum and
Griffioen, 2005), including in silico analysis of public databases
(Herbert et al., 2008; Wallgard et al., 2008), expression profiling
of cultured endothelial cells (ECs) (Engelse et al., 2008; Kut-
schera et al., 2011; Sana et al., 2005) or tumor-associated ECs
from a limited number of primary ex vivo samples (Ghilardi
et al., 2008; Seaman et al., 2007; St Croix et al., 2000; van
Beijnum et al., 2006), and genetic approaches in animal models
(del Toro et al., 2010; Sumanas et al., 2005; Weber et al., 2005).
Despite this, many components remain uncharacterized and
could offer new avenues for cancer treatment. Our study goal
was to identify regulators of tumor angiogenesis. Thus, we
analyzed the expression profile of more than 1,000 primary
human cancers to generate a vascular/angiogenesis core signa-
ture composed of geneswhose expression jointly correlates with
that of several well-recognized angiogenesis and/or EC ‘‘seed’’
genes in multiple cancers. To select uncharacterized genes
potentially involved in angiogenesis, this analysis was comple-
mented by in vivo expression profiling of antiangiogenic thera-
pies and extensive characterization of the top-ranked candidate
in different in vitro and in vivo model systems.
RESULTS
Derivation of Cancer-Type-Specific Angiogenesis/EC
Metasignatures in Different Primary Human Tumors
First, we developed an angiogenic/vascular metasignature of
genes expressed in vivo in human tumor samples derived from
different cancer types, namely 121 head and neck squamous230 Cancer Cell 24, 229–241, August 12, 2013 ª2013 The Authorscell carcinomas (HNSCCs), 959 breast
cancers (BCs), and 170 clear cell renal
cell carcinomas (CCRCCs). Coexpres-
sion networks were generated using, as
initial seeds, multiple known angiogen-
esis/EC-related transcripts previously
described as upregulated in cancer and/
or involved in angiogenesis (see tablesin Supplemental Experimental Procedures available online),
thus representing ‘‘transcriptional markers’’ of angiogenesis/
microvascular density (MVD). Seeds that passed filtering based
on expression level, coexpression, and variability (see Experi-
mental Procedures and Figures S1A–S1C) were used to derive
cancer-type-specific angiogenesis metasignatures (Figure 1;
Table S1), defining differences between tumor types. HNSCC
and BC signatures were fairly heterogeneous and composed
of three distinct gene clusters associated with different groups
of seeds (Figures 1A and 1B; see Experimental Procedures).
Different clusters might reflect the complexity/heterogeneity of
the molecular program involved in tumor angiogenesis or
different vasculature types. The CCRCC profile was more
homogeneous, with only two subclusters (Figure 1C). This is
consistent with the high angiogenic capacity of CCRCCs due
to constitutive activation of the hypoxia-inducible factor pathway
(Baldewijns et al., 2010).
Generation of a Common Angiogenesis Core Signature
and Analysis of Its Modulation by Anti-VEGF and
Anti-Notch Treatments In Vivo
A product rank score (P) generated a common angiogenesis/EC
metasignature of genes consistently highly ranked among
HNSCC, BC, and CCRCC profiles. Of 471 genes whose expres-
sion positively correlated with that of the seeds (common over-
expressed angiogenesis extended signature; top 20 in Table 1
and the full list in Table S2), the largest fraction includes genes
encoding typical EC molecules (e.g., CDH5 and ESAM) or genes
expressed by ECs, tumors, and other stromal cells (e.g.,CXCL12
and PDGFD). Overall, we observed enrichment for receptor-
coding genes and, to a lesser extent, extracellular matrix pro-
teins and transcription factors. Underexpressed genes were
heterogeneous between cancers (common underexpressed
angiogenesis signature; Table S3) and were not further consid-
ered. A core signature of 43 overexpressed genes that were
Table 1. Top 20 Genes of the Common Angiogenesis Signature
Rank Symbol Full Name HNSCC Metascore BC Metascore CCRCC Metascore Common Score
1 CDH5 cadherin 5, type 2 (vascular
endothelium)
0.9996 0.9967 0.9978 0.9941
2 ELTD1 EGF, latrophilin and seven
transmembrane domain
containing 1
0.9993 0.9967 0.9965 0.9925
3 CLEC14A C-type lectin domain family
14, member A
0.9989 0.9982 0.9924 0.9896
4 LDB2 LIM domain binding 2 0.9990 0.9967 0.9938 0.9895
5 ECSCR endothelial cell-specific
chemotaxis regulator
0.9995 0.9981 0.9913 0.9890
6 MYCT1 myc target 1 0.9969 0.9982 0.9937 0.9889
7 RHOJ ras homolog gene family,
member J
0.9989 0.9976 0.9910 0.9875
8 VWF von Willebrand factor 0.9986 0.9910 0.9959 0.9855
9 TIE1 tyrosine kinase with
immunoglobulin-like and
EGF-like domains 1
0.9989 0.9982 0.9882 0.9853
10 KDR kinase insert domain
receptor (a type III receptor
tyrosine kinase)
0.9972 0.9912 0.9967 0.9852
11 ESAM endothelial cell adhesion
molecule
0.9958 0.9971 0.9921 0.9850
12 CD93 CD93 molecule 0.9984 0.9932 0.9929 0.9845
13 PTPRB protein tyrosine
phosphatase, receptor
type, B
0.9966 0.9930 0.9936 0.9833
14 GPR116 G protein-coupled receptor
116
0.9989 0.9950 0.9872 0.9812
15 SPARCL1 SPARC-like 1 (hevin) 0.9974 0.9956 0.9878 0.9809
16 EMCN endomucin 0.9985 0.9967 0.9823 0.9776
17 ROBO4 roundabout homolog 4,
magic roundabout
(Drosophila)
0.9895 0.9967 0.9876 0.9740
18 ENG endoglin 0.9981 0.9910 0.9839 0.9732
19 TEK TEK tyrosine kinase,
endothelial
0.9992 0.9984 0.9754 0.9730
20 S1PR1 sphingosine-1-phosphate
receptor 1
0.9862 0.9979 0.9885 0.9729
See also Tables S2 and S3.
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ELTD1 and Angiogenesisconsistently top ranked in all cancers (P > 0.9; Table S2 and top
20 in Table 1) and that did not exhibit subclusters was identified,
potentially including genes highly expressed and similarly regu-
lated in tumor angiogenesis. This was substantiated by analysis
of an independent data set (Gene Expression Omnibus [GEO]
accession number GSE9014) showing increased core signature
expression in purified tumor-associated compared to normal
breast stroma (Figures S2A and S2B), suggesting a role in tumor
angiogenesis/vasculature.
To effectively select genes involved in tumor angiogenesis, we
studied modulation of the signature genes in response to antian-
giogenic treatments in preclinical models. Gene expression
analysis of treated xenograft tumors was performed using both
human- and mouse-specific microarrays to discriminate humantumor versus murine stromal (including vascular/EC) reactions.
Acute treatment with the anti-VEGF antibody bevacizumab
caused a strong downregulation of the overexpressed signature
in the stroma with a milder effect in tumor cells (Figures 2A and
2B; Table S4). The stromal effect may reflect a reduction in the
number of cells expressing these genes (e.g., ECs), a direct
effect of vascular endothelial growth factor (VEGF) blockade
(for genes such asDLL4,ESM1, andCD93, whereVEGF-induced
regulation has been reported), or treatment-induced microenvi-
ronmental factors (e.g., hypoxia). Importantly, similar results
were reported by Genentech when identifying bevacizumab-in-
hibited vascular/EC genes in tumor xenografts (Bais et al., 2011).
Interestingly, the stromal compartment exhibited a common
pool of downregulated genes under both chronic and acuteCancer Cell 24, 229–241, August 12, 2013 ª2013 The Authors 231
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Figure 2. Modulation of the Common Over-
expressed Angiogenesis Signature by Anti-
VEGF and Anti-Notch Treatment In Vivo
U87 xenografts comparing untreated tumors to
bevacizumab- (acute and chronic) or DBZ-treated
ones are shown. All overexpressed genes in the
extended common signature are shown (the top
15 are listed). Green boxes indicate the core
signature.
(A) Expression fold changes between treatments
(x axis) and control are shown (see color scale).
Genes (y axis) are ranked from highest to lowest
common score.
(B–D) Cumulative plots show the fraction of
downregulated and upregulated genes for each
treatment, for both stroma and xenograft (tumor)
expression. High values indicate a high fraction of
downregulated or upregulated genes in the com-
mon signature after treatment. Genes are shown
ranked from left to right. Plots are cumulative (that
is, the fraction is calculated down to a given rank).
See also Figure S2 and Table S4.
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ELTD1 and Angiogenesisregimens (suggesting direct VEGF induction) but also several
genes that were downregulated only by acute treatment, poten-
tially indicating angiogenesis restoration upon chronic regimen.
Under this last condition, stromal reaction also shows a small
group of upregulated genes that may be involved in resistance
(e.g., HTRA1, DCN, and MMP2 have been described as proan-
giogenicmolecules) and tumor cells responded similarly (Figures
2A and 2C; Table S4).
Treatment with DBZ, a g-secretase inhibitor, was also evalu-
ated as its therapeutic effect is mediated primarily by inducing
unproductive angiogenesis via Notch signaling inhibition in ECs
(Li et al., 2011). As this treatment increases MVD, the general
stromal signature upregulation may reflect both increased
number of transcript-expressing cells (e.g., ECs) and inhibition
of Notch signaling (Figures 2A and 2D; Table S4). DBZ treatment
showed different effects on tumor signature, inducing a mild
downregulation. Notably, both acute treatments induce hypoxia232 Cancer Cell 24, 229–241, August 12, 2013 ª2013 The Authorsby reducing perfusion, but while the
first inhibits angiogenesis, the second
induces formation of nonfunctional ves-
sels. This difference could explain why,
despite similarly affecting the signature
in tumor cells, they have opposite effects
on the stromal compartment.
TheAngiogenesis Core Signature Is
Regulated by DLL4 In Vitro
As DBZ treatment regulated our common
overexpressed signature in vivo and Dll4-
Notch signaling is a key regulator of
angiogenesis (Duarte et al., 2004; Gale
et al., 2004; Krebs et al., 2004; Phng and
Gerhardt, 2009), we evaluated the effects
of this pathway on signature expression in
primary human ECs using data from the
FANTOM4 project (http://fantom.gsc.
riken.jp/). Briefly, human umbilical veinendothelial cells (HUVECs) stimulated with recombinant human
DLL4 (rhDLL4) were analyzed using cap analysis gene expres-
sion (CAGE). This confirmed that ECs express the signature
genes and that 38% of these are regulated by DLL4 (18%
upregulated and 19.9% downregulated; Table S4), increasing
to 56% when considering the core signature (26% upregulated
and 30% downregulated).
Notably, comparing in vivo DBZ treatment with in vitro DLL4
stimulation identified a gene subset whose expression was
inversely regulated by the two approaches, as expected by their
reciprocal regulation of the Notch pathway. Despite the in vivo
signature derived from different stromal cells and the effects of
microenvironmental factors, it is likely that these are Notch-regu-
lated genes active in ECs in vivo. Regulation by DLL4 of six (of
nine) interesting and/or uncharacterized EC genes identified by
our signature and confirmed by CAGE analysis was validated
by quantitative PCR (Figure S2C).
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Figure 3. ELTD1 Vascular Expression in
Primary Human Tissues
(A) Pictures of normal tissues showing ELTD1
expression in ECs (arrowheads) and pericytes/
SMCs (arrows).
(B) IHC analysis of different primary human tumors
invariably shows vascular/EC expression (arrow-
heads).
(C) High-magnification picture showing ELTD1
expression by both ECs (arrowheads) and SMCs/
pericytes (arrows) in a tumor sample.
See also Figure S3.
Cancer Cell
ELTD1 and AngiogenesisELTD1 Selection and Expression by ECs and SMCs
We then focused on the top-ranked, relatively unstudied
G-protein-coupled receptor (GPCR) EGF, latrophilin and seven
transmembrane domain containing 1 (ELTD1). Excluding the
seeds themselves, the gene encoding this receptor ranked first
in our signature (Figure 2A; Table S2) and was significantly upre-
gulated in purified BC stroma (Figure S2B). ELTD1 is an orphan
receptor of the adhesion GPCR family; specifically, it belongs
to the epidermal growth factor-seven-span transmembrane
(EGF-TM7) receptor subfamily expressed in cardiomyocytes
and vascular smooth muscle cells (VSMCs) of the developing
rat heart (Bjarnado´ttir et al., 2004; Kwakkenbos et al., 2004;
Nechiporuk et al., 2001). Importantly, Eltd1 knockout (KO) mice
develop normally but present increased cardiac hypertrophy in
response to pressure overload (Xiao et al., 2012). ELTD1 upregu-
lation in glioblastoma, both in tumor cells and ECs, has recently
been reported (Dieterich et al., 2012; Towner et al., 2013). Here,
Eltd1 expression was affected in stromal cells by both acute anti-
VEGF and anti-Notch treatments in vivo (Table S4), with DBZ-
induced upregulation being consistent with the reciprocal reduc-
tion observed in HUVEC stimulated by DLL4 in vitro (Table S4;
Figure S2C), the latter confirming Eltd1 observed upregulation
in retinal ECs from Dll4+/ mice (del Toro et al., 2010). Studies
of the recombinant rat ortholog indicate that Eltd1 is expressed
on the cell surface (Nechiporuk et al., 2001), and we confirmed
this by fluorescence-activated cell sorting analysis of 293T cells
overexpressing an N-terminally tagged human ELTD1 (Fig-
ure S5A). This is an important confirmation for potential thera-
peutic strategies.
Despite reports of vascular ELTD1 transcript (Herbert et al.,
2008; Nechiporuk et al., 2001; Sumanas et al., 2005; WallgardCancer Cell 24, 229–241et al., 2008; Weber et al., 2005) and
protein expression in human tissues
(Sigma Human Protein Atlas) (Uhlen
et al., 2010), expression patterns in both
cancer and normal samples have only
been reported for glioma and normal
brain (Dieterich et al., 2012; Towner
et al., 2013). Thus, we validated an anti-
body for ELTD1 detection by immunohis-
tochemistry (IHC) and western blotting
(Figures S3B and S3C).
IHC of tissue microarrays (TMAs) con-
taining primary human tumor samples
(65 head and neck, 157 renal, 120 colo-rectal, 200 ovarian, and a few other tumor types), normal tissues
(148 renal and 120 colorectal; of these, 126 and 120 were
matched to tumor samples, respectively), and reactive tonsil
sections was performed to study ELTD1 protein expression.
ELTD1 was detected in the majority of ECs in tumor and
normal tissues (Figures 3A and 3B). Despite some variability,
stronger positivity was observed in tumor-associated compared
to normal ECs (Figures 3B, 4A, 4B, 4H, and 4I; Figures S4C and
S4D; see below). Arteries and arterioles, occasionally seen in
tumors, showed high ELTD1 staining in VSMCs (Figures 3A
and 3C), generally stronger than in neighboring ECs. Vascular
ELTD1 protein expression is consistent with existing data,
although a comparative analysis between ECs and VSMCs/
pericytes was not previously reported. Immunofluorescence
analysis for ELTD1 and CD34/a-SMA (EC and SMC marker,
respectively) confirmed expression by both cell types (Fig-
ure S3D). ELTD1 labeling of neoplastic cells was observed in a
minority of cases and generally as weak cytoplasmic positivity.
However, strong tumoral ELTD1 expression was observed in
some tumor types (Figure S3E).
Clinical Relevance of EC ELTD1 in Renal, Head and
Neck, Colorectal, and Ovarian Cancer
Extensive analysis in head and neck, renal, and colorectal
cancers showed predominantly negative/weak positivity in
tumor cells. Interestingly, on comparing tumor and normal
matched tissues, we observed a clear increase in ELTD1 expres-
sion in tumor-associated ECs. Indeed, 89% of renal (110/124
samples) and 82% of colorectal cases (98/119 samples) showed
increased EC ELTD1 staining (Figures 4A and 4B; Figures S4C
and S4D). EC upregulation was also observed in ovarian cancer,, August 12, 2013 ª2013 The Authors 233
Figure 4. Endothelial ELTD1 Expression in
Cancer and Normal Matched Tissues and
Its Prognostic Value
(A) Representative IHC pictures of ELTD1 scoring
in renal tissue (scores 1 and 2 are from normal
kidney while 3 and 4 are from renal cancer).
(B) ELTD1 expression in renal cancer and normal
matched kidney. Each column represents a
patient with red and white bars showing the score
in tumor-associated and normal ECs, respec-
tively. Horizontal lines represent score averages.
(C and D) Significant correlation between cancer-
specific survival and both tumor-associated EC
ELTD1 expression (C) and the differential EC score
(tumor minus normal) (D).
(E) Representative IHC pictures of ELTD1 score
categories in head and neck cancer.
(F) Summary of ELTD1 expression. Each column
represents a patient and the horizontal line
represents the average.
(G) Significant correlation between tumor-associ-
ated EC ELTD1 expression and overall survival.
HR, hazard ratio.
(H) Representative IHC pictures of ELTD1 score
categories in human ovarian tissue (scores 0 and 1
are from normal ovary while scores 2 and 3 are
from ovarian cancer).
(I) Summary of EC ELTD1 expression in normal
and neoplastic ovarian tissue shows upregulation
in tumor samples.
(J) Significant correlation between tumor-
associated EC ELTD1 levels and overall survival.
Arrowheads indicate blood vessels.
See also Figure S4 and Tables S5–S7.
Cancer Cell
ELTD1 and Angiogenesisalbeit in a small series (Figures 4H and 4I). These findings are
consistent with data previously reported in glioma (Dieterich
et al., 2012).
Interestingly, higher EC ELTD1 levels significantly correlated
with increased MVD in renal, head, neck, and colorectal cancer
(Figure S4F), suggesting an involvement in tumor angiogenesis.
Furthermore, expression profiling of HNSCC cases showed a
significant inverse correlation between ELTD1 messenger
RNA (mRNA) levels and a published hypoxia signature (Buffa
et al., 2010) or the hypoxia-inducible gene CA9 (Figure S4G),
possibly suggesting better perfusion of tumors with high
ELTD1.
In renal cancer, higher ELTD1 scores in tumor-associated
ECs correlated with smaller tumor size (Table S5; p = 0.03)
and improved cancer-specific (Figure 4C) and overall survival
(Figure S4A). Notably, analyzing the differential score between
tumor-associated and normal ECs gave similar results, with
bigger differences correlating with smaller tumor size (p =
0.02) and improved cancer-specific survival (Figure 4D). In
HNSCC (Figures 4E and 4F), higher EC ELTD1 expression
identified less aggressive tumors, correlating with lower UICC234 Cancer Cell 24, 229–241, August 12, 2013 ª2013 The Authorsstage (p = 0.02), less perineural invasion
(p = 0.03), borderline trend toward lower
pT value (p = 0.08; Table S6), and
improved overall survival (Figure 4G).
Colorectal cancer showed borderline
significant associations between thehighest EC ELTD1 scores (score 4) and tumor differentiation
status (p = 0.05; Table S7) and improved overall survival (Fig-
ure S4E). Finally, higher EC ELTD1 significantly correlated
with improved overall survival in ovarian cancer (Figure 4J).
These results demonstrate clinical relevance across four
different tumor types and identify a potential role for EC
ELTD1 in cancer biology.
ELTD1 Is Glycosylated in the Extracellular Domain and
Expressed as Monomer and Multimers
Analysis of HUVEC and ELTD1-transfected 293 cell lysates
showed multiple bands, with molecular weights (MWs) ranging
between 95 and 70 kDa (the expected MW was 78 kDa; Fig-
ure 5A). To assess if this reflected posttranslational modifica-
tions (e.g., N-glycosylation) or alternative splicing, lysates were
subjected to glycosidase digestion prior to analysis. ELTD1
MW was sensitive to endoglycosidase H (EndoH), shifting the
lowest band to 44 kDa, while Peptide:N-glycosidase F
(PNGase) treatment shifted all forms to a similar 44 kDa band
(Figure 5A). Thus, different forms derive from glycosylation of a
single protein. The antibody used binds the ELTD1 extracellular
Figure 5. ELTD1 Expression, Regulation,
and Function in Primary Human Endothelial
Cells In Vitro
(A) HUVEC- and ELTD1-overexpressing 293 cell
lysates were treated with deglycosylating
enzymes before western blotting (WB) analysis.
Untreated samples show multiple bands that are
lost after treatment with contemporary appear-
ance of a lower MW band corresponding to the
deglycosylated ECD.
(B) WB analysis of DLL4-stimulated HUVECs
shows ELTD1 downregulation at different time
points (bars represent average ±SD of band
densitometric analysis).
(C) Similar analysis on HUVECs treated with
different cytokines for 24 hr (bars represent
average ±SD of band densitometric analysis).
(D) WB validation of ELTD1 silencing with two
different siRNAs. *Nonspecific band appearing
with long exposure.
(E) HUVEC sprouting is reduced by ELTD1
silencing (bars represent mean ±SD). Represen-
tative spheroids are shown.
(F) In vitro cell fate assay. Sprouting analysis from
spheroids composed of a 1:1 ratio between
prelabeled control and siELTD1 cells. ELTD1
silencing impairs the ability to take the tip cell
position (arrows) without affecting stalk cell for-
mation (graph shows the number of tip and stalk
cells as the average percentage ±SD).
See also Figure S5.
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ELTD1 and Angiogenesisdomain (ECD) and the MW observed after deglycosylation
matches that predicted for the ECD alone (Figure S5C). This is
consistent with reports that rat eltd1 is expressed as a noncova-
lent heterodimer composed of the ECD and transmembrane
domains (Nechiporuk et al., 2001) (Figure S5B). Accordingly, a
human ELTD1-ECD-FC fusion protein was expressed as a single
form with comparable MW to the highest glycosylated molecule
in HUVEC plus the tag (Figure S5D). PNGase treatment
confirmed glycosylation of the recombinant ECD-FC (Fig-
ure S5E), indicating that only the ECD is detected under dena-
turing conditions. GPCRs are known to form homomers and
heteromers (Casado´ et al., 2009), and analysis of cell lysates
under nondenaturing conditions identified four ELTD1 main
forms, consistent with the MWs of a glycosylated homomo-
nomer, homodimer (predominant), homotrimer, and homote-Cancer Cell 24, 229–241tramer (Figure S5F), although interac-
tion with other molecules cannot be
excluded.
ELTD1 Is Regulated by Both DLL4
Signaling and Proangiogenic
Cytokines
ELTD1 transcript expression is regulated
by DLL4-induced signaling in vitro (Table
S4; Figure S2C), and analysis of DLL4-
stimulated HUVECs confirmed that pro-
tein levels are also significantly reduced
(Figure 5B). Although the DLL4-NOTCH
pathway plays a relevant role in angio-genesis, this cannot explain ELTD1 upregulation observed in
tumor-associated ECs. Factors such as VEGF and basic fibro-
blast growth factor (bFGF) are additional key players in tumor
angiogenesis (Carmeliet and Jain, 2011a), and both increased
ELTD1 mRNA (not shown) and protein levels in HUVECs, having
an additive effect in combination (Figure 5C), possibly contrib-
uting to increased ELTD1 expression in tumor-associated ECs.
ELTD1 Silencing Reduces HUVEC Adhesion and Inhibits
Sprouting and Tip Cell Phenotype In Vitro
To study ELTD1’s role in EC biology, in vitro gene silencing was
functionally evaluated in HUVECs using two different small
interfering RNAs (siRNAs) (Figure 5D). ELTD1 function is un-
known and initial experiments indicated silencing had no effect
on EC viability in normal culture conditions (Figure S5H). Other, August 12, 2013 ª2013 The Authors 235
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(Kwakkenbos et al., 2004) but are low or undetectable in ECs
(Figure S5G). As the ELTD1 ligand is unknown, Matrigel was
used to evaluate the role of ELTD1 in adhesion. Gene knock-
down slightly, but significantly, reduced EC adherence (Fig-
ure S5I), although this is insufficient to demonstrate direct
involvement in cell adhesion. General migratory ability, evalu-
ated by the wound-healing assay, showed no change (data
not shown). Using an in vitro three-dimensional spheroid-based
angiogenesis assay, ELTD1-silenced HUVECs showed reduced
angiogenic ability, generating fewer sprouts (50%–60%)
compared to control (Figure 5E). This phenotype represents a
functional explanation for both VEGF/bFGF-induced ELTD1
upregulation and DLL4-induced repression, as VEGF and
bFGF are known to induce EC sprouting while Dll4 is a negative
regulator of this process through the restriction of tip cell
phenotype/specification (Hellstro¨m et al., 2007; Phng and
Gerhardt, 2009). Hypothesizing a role in tip cell biology, a cell
fate assay was performed using spheroids composed of a 1:1
mixture of control and ELTD1-silenced HUVECs, both prela-
beled with different fluorescent dyes. Consistent with our previ-
ous experiments showing reduced sprouting, ELTD1-silenced
HUVEC showed a reduced ability to take the tip position
compared to control cells (37.9% ± 5.8% versus 62.1% ±
5.8%, respectively; Figure 5F). This demonstrates that ELTD1
plays an intrinsic role during the sprouting process. Importantly,
although stalk cell number was expected to increase, gene
knockdown did not affect this cell subpopulation, possibly
because of back migration to the spheroid (Figure 5F). This
finding confirms ELTD1’s role only in tip cell function/
specification.
ELTD1 Is Involved HumanUmbilical Vein SmoothMuscle
Cell Viability and Adhesion
As VSMC express ELTD1, we evaluated silencing consequences
(Figure S5J) in this cell type in vitro. Opposite to observations in
ECs, ELTD1 knockdown caused a significant reduction in cell
viability 72 hr after transfection (Figure S5K). Similarly to EC,
adhesion to Matrigel was significantly reduced while no effect
on general migratory ability was observed (Figure S5L and
data not shown).
Eltd1 Is Expressed in the Zebrafish Embryo Vasculature
and Has a Role Antagonizing dll4 in Blood Vessel
Development
To investigate ELTD1’s role in vivo, we exploited the devel-
oping zebrafish embryo model, being the only member of its
receptor family conserved in this species (Kwakkenbos et al.,
2004). Eltd1 expression was assessed by in situ hybridization.
During gastrulation, expression was ubiquitously detected
throughout the embryo (Figure 6A1) while by eight somites it
was observed in the posterior lateral plate mesoderm in bilat-
eral stripes (Figure 6A2, arrows). This group of cells has been
described as the posterior hemangioblast population, contain-
ing cells that give rise to both ECs and blood cells (Gering
et al., 1998). As these cells migrate to the midline (Figure 6A3)
and form the dorsal aorta (DA) and the posterior cardinal vein
(PCV) (Figure 6A4), eltd1 expression was still detectable. By
27 hr postfertilization (hpf), the distinction between the DA236 Cancer Cell 24, 229–241, August 12, 2013 ª2013 The Authorsand PCV is complete and intersegmental vessels (ISV), formed
by EC sprouting from the DA, also express eltd1 (Figure 6A5,
arrowheads). By 48 hpf, weaker eltd1 expression is still
detected in ECs (Figure 6A6). The lack of eltd1 in the cloche
zebrafish mutant (Figure S6A), which has severe defects in
blood and endothelium formation (Xiong et al., 2008), confirms
its EC association.
To study the role of eltd1 during development, we designed
two antisense morpholinos (MOs) targeting the start codon
(ATGMO) and a splicing junction (spliceMO) of the eltd1 pre-
mRNA, respectively (Figure S6B), and injected them into sin-
gle-cell embryos. RT-PCR analysis confirmed eltd1 knockdown
by the spliceMO (Figure S6C, compare lanes 4 and 5). By using
Tg(kdrl:GFP) transgenic embryos, in which the vasculature ex-
presses GFP, we consistently observed severe vascular defects
during the formation of the ISV at 30 hpf when eltd1 ATGMO (Fig-
ure S6D) or eltd1 spliceMO was injected. Although both MOs
gave the same phenotype, here we show data for the eltd1
ATGMO where approximately 90% of embryos showed the
phenotype. Confocal time lapse microscopy imaging of unin-
jected and eltd1 ATGMO-injected Tg(kdrl:GFP) embryos allowed
us to follow the trunk development in detail. In eltd1morphants,
defects start as early as 22 hpf, the time when the primary
sprouts from the DA giving rise to ISV start to develop (Isogai
et al., 2003) (Figure 6B; Movies S1 and S2). In eltd1 morphants,
the formation of ISV sprouts is blocked (Figure 6B, arrows) or
severely reduced (Figure 6B, arrowheads), never reaching the
dorsal position observed in wild-type (WT) siblings (Figure 6B,
asterisks). Similar defects were observed by assessing expres-
sion of another vascular-related gene, fli1, by in situ hybridization
(Figure S6E, 1 and 4).
As ELTD1 is repressed by DLL4 in vitro (Figure 5B; Fig-
ure S2C; Table S4) and loss of eltd1 function in zebrafish leads
to impaired sprouting, a phenotype opposite to that associated
with dll4 inhibition (Hellstro¨m et al., 2007; Siekmann and
Lawson, 2007), we explored this potential connection by dis-
rupting dll4 function in embryos and analyzing eltd1 expression
as well as by assessing dll4 expression in eltd1 morphants
(Figure S6E). As these genes negatively regulated each other
(Figures S6E2, S6E5, S6E3, and S6E6), we attempted to rescue
the ISV phenotype observed in eltd1 morphants by dll4
silencing. Tg(kdrl:GFP) embryos were injected with eltd1 MO,
dll4 MO, or both and analyzed at 52 hpf (Figure 6C). Eltd1 mor-
phants showed severely impaired ISV formation, from pre-
venting ISV formation (arrow) to severe growth retardation
(Figures 6C3 and 6C4, arrowhead), as observed at earlier
stages (Figure 6B; Figures S6D and S6E; Movies S1 and S2),
while dll4 MO recapitulated the previously reported arterial
hyperbranching phenotype (Figures 6C5 and 6C6, asterisks)
(Leslie et al., 2007). However, coinjection of eltd1 and dll4MOs,
at concentrations causing ISV defects and arterial hyper-
branching, respectively, rescued ISV development in 52% of
embryos (Figures 6C7 and 6C8; Figure S6F). Moreover, the
excessive arterial angiogenesis caused by dll4 depletion was
also rescued in 55% of embryos (Figures 6C7 and 6C8; Fig-
ure S6F). A concordant finding was observed at the histological
level, since tip cell/sprouting structures were increased in dll4
MO embryos but were almost normalized in double morphants
(Figure S6G).
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Figure 6. Eltd1 Expression and Function
during Vascular Development in Zebrafish
(A) Eltd1 in situ hybridization at different develop-
mental stages shows expression in ECs and blood
precursor cells (arrow) and developing vessels:
DA, PCV, ISV (arrowheads), and vascular plexus
(asterisk).
(B) Time-lapse confocal microscopy of
Tg(kdrl:GFP) uninjected and eltd1 morphants
every 90 min. In eltd1morphants, the formation of
ISV sprouts is blocked (arrows) or severely
reduced (arrowheads), never reaching the dorsal
position observed in WT siblings (asterisks).
(C) Lateral views of uninjected control (C1 and C2)
and different morphants (C3–C8) 52hpf
Tg(kdrl:GFP) embryos. Trunk vessels imaging re-
vealed a failure to form ISV in eltd1morphants (C3
and C4, arrow and arrowhead), which is rescued in
eltd1+dll4 double morphants (C7 and C8). The dll4
morphant arterial hyperbranching phenotype (C5
and C6, asterisks) is also rescued in the eltd1+dll4
double morphants (C7 and C8). Scale bars:
100 mm.
(D) Working hypothesis.
See also Figure S6 and Movies S1 and S2.
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ELTD1 and AngiogenesisEffects of In Vivo Eltd1 Gene Silencing during Tumor
Growth
Based on our findings, we hypothesized that ELTD1 played a role
in tumor angiogenesis. Using two mouse Eltd1-specific siRNAs
(Figures S7A and S7B), we silencedmurine Eltd1 in an orthotopic
model of ovarian carcinoma by intravenous injection of Eltd1
siRNA incorporated into chitosan nanoparticles (CH-NP). This
approach was highly efficient for in vivo EC gene silencing (Lu
et al., 2010) and did not trigger an interferon response (Fig-
ure S7C). One week after intraperitoneal injection of SKOV3ip1
cells, mice were randomly allocated to treatments (control
siRNA/CH-NP or Eltd1 #1 siRNA/CH-NP). Treatment with Eltd1
#1 siRNA/CH-NP resulted in a significant decrease in tumor
weight (67% reduction; Figure 7A) and nodule number (Fig-
ure 7B); results were confirmed by a second Eltd1 siRNA (siRNACancer Cell 24, 229–241#2; Figures S7E and S7F). Effects on
tumor growth were associated with dra-
matic increase in survival (Figure 7C) and
reduced metastatic dissemination (Fig-
ure 7I). Importantly, in the survival experi-
ment, seven out of nine Eltd1 siRNA/CH-
NP-treatedmicewere sacrificedwhile still
healthy to finish the experiment on day
101 after tumor cell injection (44 day
mean survival for the control group).
These mice showed very small nodules
(n = 5) or undetectable tumors (n = 2), con-
firming that Eltd1 silencing maintained
the tumor growth inhibition observed in
previous short-term experiments.
To identify mechanisms by which stro-
mal Eltd1 silencing could reduce tumor
growth, we examined different histologic
markers. Eltd1 knockdown significantlyreduced MVD (Figure 7D) compared to control treatment,
consistent with increased hypoxia (Figure 7F), significant reduc-
tion in cell proliferation (Figure 7E), and increased EC apoptosis
(Figure 7G). Pericyte coverage was increased (Figure 7H). No
effect on macrophage infiltration was observed (Figure S7D).
To exclude model-specific effects, Eltd1 silencing (siRNA #1)
was also performed in a subcutaneous colorectal cancer model.
Eltd1 knockdown (Figure S7K) in HCT116 xenografts caused sig-
nificant growth reduction associated with histologic changes
similar to those observed in SKOV3ip1 tumors (Figures S7J
and S7M).
Anti-Eltd1 treatment was well tolerated (Figure S7G) and did
not cause observable heart changes, which were described in
Eltd1 KO mice under cardiac pressure overload (Xiao et al.,
2012) (Figures S7G, S7I, and S7L)., August 12, 2013 ª2013 The Authors 237
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tumor weight (A) and nodule number (B) in a
SKOV3ip1 orthotopic mouse model.
(C) Reduced tumor growth was associated with a
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(D–H) Analysis of tumor tissue sections shows that
Eltd1 silencing reduces MVD (D; CD31 IHC) and
tumor tissue proliferation (E; Ki67 IHC) but also
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apoptosis (G; CD31/TUNEL immunofluorescence
[IF]), and vascular pericyte coverage (H; CD31/
desmin IF). Representative pictures are shown.
Arrows indicate blood vessels within insets. Scale
bars: 50 mm.
(I) Drastic reduction in metastatic spread upon
Eltd1 silencing was also observed. All graph bars
represent average ±SEM (unpaired t test).
See also Figure S7.
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ELTD1 and AngiogenesisDISCUSSION
Our approach is based on global expression profile analysis of a
large number of unfractionated primary human tumors to
infer cancer-type-specific angiogenesis/vascular signatures
composed of genes whose expression correlated with that of
multiple seeds (vascular/angiogenesis genes used as transcrip-
tional markers ofMVD/angiogenesis). Interestingly, multiple sub-
signatures were observed, suggesting the existence of different
angiogenic/vascular programs in distinct patient subsets, further
demonstrating interindividual variability, possibly explained by
different ‘‘stage or type of angiogenesis’’ (e.g., vessel matura-
tion) or triggering condition (e.g., different proangiogenic factors)238 Cancer Cell 24, 229–241, August 12, 2013 ª2013 The Authorsthat might have clinical relevance. While
HNSCC and BC presented three distinct
clusters, CCRCC presented a more
compact profile composed of only two
subclusters. Notably, two main types of
blood vessels with opposite prognostic
value have been reported in CCRCC
(Yao et al., 2007).
A 43-gene compact common signature
was extracted from the cancer-type-
specific ones. This core signature
included known angiogenesis molecules
(e.g., KDR, ROBO4, RHOJ, GPR124,
CLEC14A, TIE1, ENG, and TEK/TIE2),
proteins reported to be upregulated in
tumor angiogenesis (e.g., CLEC14A,
CD93, ROBO4, ENG, TEK/TIE2, RGS5,
and ACVRL1/ALK1), and genes not yet
implicated in vascular biology or generally
not well characterized (e.g., ELTD1,
GPR116, and MYCT1). This signature is
enriched for typical EC molecules (e.g.,
CDH5, VWF, andESAM) but also contains
transcripts likely to be derived from tumor
and other stromal cells (e.g., PDGFD).We described upregulation of this signature in the
stromal component of primary BC and hypothesize that this
might represent a core program in tumor angiogenesis/
vasculature whose expression is unrelated to the cancer type
or proangiogenic stimulus, therefore explaining its com-
pactness. Confirmation would offer future targets for therapy
that might be less sensitive to interindividual variability.
Indirect validation of the involvement of these genes in tumor
angiogenesis was also indicated by their altered expression in
antiangiogenesis therapeutic tumor models. Both anti-VEGF
and anti-Notch therapies induced changes in signature ex-
pression mainly in the murine stroma rather than the human
xenograft.
Cancer Cell
ELTD1 and AngiogenesisThis core signature was also evaluated in ECs stimulated by
DLL4, a key regulator of angiogenesis (Phng and Gerhardt,
2009). Nearly two-thirds of the signature is modulated by
DLL4-NOTCH signaling, further suggesting its relevance in EC
biology. As simple expression does not prove functional activity,
we focused on the top-ranked, relatively unstudied molecule
ELTD1, a GPCR with transcript expression in ECs (Herbert
et al., 2008;Wallgard et al., 2008) that is lost in zebrafish embryos
lacking blood vessel development (Sumanas et al., 2005; Weber
et al., 2005) and upregulated in glioblastoma ECs and tumor cells
(Dieterich et al., 2012; Towner et al., 2013). Recent data from
Eltd1 KO mice also proved that this gene is dispensable for
normal development but has a role in heart adaptation to patho-
logic conditions such as pressure overload (Xiao et al., 2012).
Here, we report ELTD1 protein expression in both ECs and
VSMCs, as the other members of this receptor family are primar-
ily expressed by immune cells (Kwakkenbos et al., 2004). ELTD1
is expressed as a highly glycosylated molecule, as suggested by
Liu et al. (2005), in monomeric and predominantly dimeric forms.
EC ELTD1 expression is reduced by Dll4-Notch signaling in vitro
and in vivo but induced by VEGF and bFGF. Functionally, we
prove that ELTD1 plays a key role in angiogenesis both in vitro
and in vivo, and our data suggest the mechanism may be via
regulation of the sprouting process. The dramatic vascular
impairment in zebrafish embryos lacking eltd1 while Eltd1 KO
mice do not present any developmental defect (Xiao et al.,
2012) might reflect compensatory mechanisms acquired during
evolution, consistent with receptor family expansion in higher
vertebrates (Kwakkenbos et al., 2004). However, a potential
caveat of the KO strategy of Kwakkenbos et al. is the retention
of the entire Eltd1 extracellular domain. Thus, we cannot exclude
that functionally active soluble Eltd1 or aberrant membrane re-
ceptor forms may be expressed. Nevertheless, taken together
with the rest of our data, the simplest interpretation of our in vivo
siRNA data is that Eltd1 is important for promoting tumor growth
and metastasis by playing a role in pathologic angiogenesis.
Further insights into the specific cell types and mechanisms
contributing to impaired tumor growth following Eltd1 silencing
might be gained with conditional Eltd1 KO mice. Importantly,
systemically given Eltd1 siRNAs were nontoxic in mice as as-
sessed by body weight, heart to body weight ratio, and heart
histology, indicating a differential role of Eltd1 in normal versus
tumor vasculature and safety of its inhibition in animals without
pre-existing cardiac pathologies.
ELTD1 modulates vascular sprouting by regulating tip cell
specification/activity, possibly in part by negatively affecting
DLL4 expression (Figure 6D). Functional interplay between dll4
and eltd1 pathways is also proven by their reciprocal phenotypic
rescue in double-MO zebrafish embryos. Importantly, eltd1
plays a dll4-independent role during vascular development since
dll4 MO-mediated functional rescue in eltd1-deficient embryos
only partially restores normal phenotype.
Analysis of human samples demonstrated ELTD1was upregu-
lated in tumor-associated ECs in renal, colorectal, and ovarian
cancers compared to their normal corresponding control
tissues. Despite being extensively used in research and clinical
settings, IHC is semiquantitative and further studies are required
to accurately quantify ELTD1 levels in the normal and tumor
endothelium. However, limited mRNA analyses (breast and renalcancer data not shown; Dieterich et al., 2012) indicate a 2- to
4-fold increase in ELTD1 transcripts in tumor versus normal
ECs. This fits with the VEGF/bFGF induction of ELTD1, as these
cytokines are often upregulated in cancer, playing a key role in
tumor angiogenesis. Importantly, the positive correlation be-
tween ELTD1 levels and MVD observed in patient samples rep-
resents an indirect validation of the proangiogenic function
described in vitro and in vivo. Clinically, higher EC ELTD1 levels
correlated with less aggressive cancer features and better prog-
nosis in all tumor types analyzed. Although many angiogenic
molecules correlate with poor survival, clearly some must also
be associated with the vasculature of those with better outcome.
In most studies of tumor vessels, no note is made of protein
expression level in adjacent normal vessels from the same pa-
tient, although it likely there will be substantial variability from
person to person. In our study, the differences between tumor
and normal expression translate into a greater difference in
outcome, suggesting the importance of assessing the host
background in future studies. The concept of ‘‘vascular normal-
ization’’ in response to anti-VEGF therapy has been well
described (Carmeliet and Jain, 2011b). However, if tumors
were better perfused prior to therapy (because of higher MVD,
more differentiated vessels, and/or reduced leakiness), then
there would be less hypoxia and intratumoral pressure and
potentially less aggressive cancer. Higher ELTD1 levels, promot-
ing EC sprouting, may improve tumor vascularization and perfu-
sion, thus aiding drug delivery. This hypothesis needs further
validation but is consistent with the findings that high EC
ELTD1 levels correlate with higher MVD and longer survival.
Therapeutic potential is suggested by ELTD1 upregulation in
tumor ECs and the dramatic impairment in tumor growth upon
its silencing. This latter is probably caused by MVD reduction,
consistent with the positive correlation observed between
ELTD1 levels and MVD in clinical samples and functionally ex-
plained by ELTD1’s proangiogenic role identified in vitro and
in vivo during zebrafish development.
Analyzing ELTD1 expression in prospective randomized
studies of antiangiogenic therapies will determine if there is
any modulation during vascular normalization and if it is an
intrinsic mechanism of resistance to anti-VEGF therapy, possibly
offering combined antiangiogenic treatments. The latter may
help explain the lack of efficacy of antiangiogenic therapies in
the adjuvant situation if smaller earlier lesions have a different
type of vasculature. The observation that higher ELTD1 levels
correlate with better outcome does not obviate it as a therapeu-
tic target as observed for other good prognostic markers (ALK in
T cell lymphomas, estrogen receptor in relapsed BC, andMVD in
renal cancer). Of note, even within the high-expressing group of
patients, a relevant fraction die of their disease. Furthermore, a
good prognosis may relate to a more mature vasculature resis-
tant to metastasis. Clinically, ELTD1 represents a relevant cell-
surface candidate for targeted antiangiogenic approaches
whose safety is suggested by target upregulation in tumor
ECs, normal development of KO mice (Xiao et al., 2012), and
lack of visible toxic effects in our in vivo experiments. However,
safety in humans would need to be verified in clinical trials,
possibly focusing on patients with high EC ELTD1 levels and
no cardiac impairment. Furthermore, if subsequent studies
demonstrate ELTD1 involvement in vessel maturation, then itsCancer Cell 24, 229–241, August 12, 2013 ª2013 The Authors 239
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ELTD1 and Angiogenesisinhibition might also be considered for combination therapies to
sensitize vasculature to anti-VEGF or anti-Notch therapies. Our
work shows clear therapeutic effects of Eltd1 targeting and a
role in vascular sprouting.
EXPERIMENTAL PROCEDURES
Gene Expression Profiling and Derivation of Cancer Type-Specific
and Core Angiogenesis Signatures
A coexpression network was constructed using seed clustering and meta-
signatures derived as described previously (Buffa et al., 2010). Prototype
genes (seeds) were selected on the basis of published evidence of involvement
in angiogenesis, and/or expression in vessels (table in Supplemental Experi-
mental Procedures). Patients treated in Oxford were analyzed and other
data sets were retrieved from the National Center for Biotechnology Informa-
tion’s GEO (http://www.ncbi.nlm.nih.gov/geo/) (table in Supplemental Experi-
mental Procedures) for a total of 121 HNSCCs, 959 BCs, and 170 CCRCCs.
Patients and Tissue Samples
Formalin-fixed, paraffin-embedded tumor tissues from 157 patients with renal
cancer (plus 148 normal kidney samples; 126 matched to tumor cases), 120
with colorectal cancer (plus 120 matched normal tissues), 65 with head and
neck cancer, and 21mixed tumor types were used to assemble TMAs (Buben-
dorf et al., 2001). Demographic and pathological details of renal, head and
neck, and colorectal cancer cases are reported in Supplemental Information.
Ovarian cancer TMA and patient data (n = 200) were previously reported (Lu
et al., 2010). Whole tissue sections from 11 cases of ovarian serous adenocar-
cinoma, five normal ovaries, and reactive tonsil were also analyzed. Samples
were obtained in accordance with the National Research Ethics Service South
Central Oxford B Research Ethics Committee (project reference number
C02.216). Deidentified samples were accessed through the Oxford Centre
for Histopathology Research according to UK regulatory requirements.
Orthotopic In Vivo Model of Ovarian Cancer
Female athymic nudemice (NCr-nu) purchased from the National Cancer Insti-
tute Frederick Cancer Research and Development Center (Frederick, MD)
were maintained as previously described (Lu et al., 2010). All mouse studies
were approved by the MD Anderson Cancer Center Institutional Animal Care
and Use Committee. Themice used for in vivo experiments were 8 to 12 weeks
old. SKOV3ip1 (13 106 cells per mouse) or HCT116 (13 106 cells per mouse)
cells were injected intraperitoneally or subcutaneously, respectively. Mice
were monitored daily for adverse effects and were sacrificed when any of
the mice seemed moribund.
To assess tumor growth, treatment began 1 week after cell injection. Each
siRNA (Sigma-Aldrich) was incorporated into chitosan nanoparticles (Han
et al., 2010; Lu et al., 2010) and given twice weekly (150 mg/kg body weight)
through intravenous injection. After screening (Figures S7A and S7B),
mouse eltd1-specific siRNA 85 (#1) and 53 (#2) were selected (#1:
50-GTTGCATTCCTCTGCTATA-30; #2: 50-GTTGAAAGGAGTACACATA-30).
For tumor growth studies (n = 10 per group), treatment continued until any
experimental group became moribund (control, typically 4 or 5 weeks), while
for the survival experiment (n = 9 per group) treatment continued for
101 days, with individual mice being sacrificed as they became moribund.
Mouse, heart, and tumor weight, number of nodules, and distribution/number
of metastasis were recorded at the time of sacrifice. Mouse weight was also
recorded weekly during treatment. Tissue specimens were fixed with formalin
or optimum cutting temperature (Miles) or were snap frozen. To exclude treat-
ment-induced interferon response, healthy animals (n = 3 per group) were
treated with a single dose of saline, naked CH-NP, or Eltd1 #1 siRNA CH-
NP. Blood sampled 12 hr after injection was tested with ELISA for immunosti-
mulatory cytokines (R&D Systems).
Statistical Analysis
Survival was measured from the day of surgery. The log-rank test was used in
univariate survival analyses. Prognostic factors were evaluated in Cox pro-
portional hazards regression including relevant clinical covariates (see Tables
S5–S7); backward stepwise likelihood was used for selection. Other paired or240 Cancer Cell 24, 229–241, August 12, 2013 ª2013 The Authorsunpaired parametric or nonparametric tests were used as necessary;
methods, statistics, and significance are cited in the text and figures. Stata
11.0, GraphPad Prism 5.00, and R were used.
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